NAS
ADMA icon

Nykredit A/S’s ADMA Biologics ADMA Stock Holding History

Nykredit A/S’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$59.5K Buy
+7,104
New +$64.8K ﹤0.01% 1456

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Nykredit A/S's ADMA Position: Q2 2026 in Review

Nykredit A/S opened a new position in ADMA Biologics (ADMA) in Q2 2026: 7,104 shares worth $59.5K. The stake represents ﹤0.01% of the portfolio and ranks #1456 among its holdings.

241 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Nykredit A/S held 7,104 shares of ADMA Biologics worth $59.5K as of Q2 2026.
  • ADMA Biologics was a new Nykredit A/S position in Q2 2026.
  • ADMA Biologics made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #1456 holding.
  • 241 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.